Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Investing Activities (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Cash from Investing Activities for 3 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 121.98% to -$3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$93.3 million through Dec 2025, down 299.49% year-over-year, with the annual reading at -$93.3 million for FY2025, 299.49% down from the prior year.
  • Cash from Investing Activities hit -$3.4 million in Q4 2025 for Compass Therapeutics, up from -$95.2 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $29.0 million in Q3 2024 to a low of -$95.2 million in Q3 2025.
  • Historically, Cash from Investing Activities has averaged -$1.6 million across 3 years, with a median of $5.3 million in 2023.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 1071.96% in 2024 and later crashed 427.92% in 2025.
  • Year by year, Cash from Investing Activities stood at $6.3 million in 2023, then skyrocketed by 143.43% to $15.4 million in 2024, then plummeted by 121.98% to -$3.4 million in 2025.
  • Business Quant data shows Cash from Investing Activities for CMPX at -$3.4 million in Q4 2025, -$95.2 million in Q3 2025, and -$6.4 million in Q2 2025.